Stock Track | Alnylam Pharmaceuticals Plunges 7.45% in Pre-market as Q2 Revenue Misses Estimates
Stock Track
Jul 30
Alnylam Pharmaceuticals (ALNY) shares tumbled 7.45% in pre-market trading on Thursday after the company reported second-quarter revenue that fell short of analyst expectations.
The biotech firm posted revenue of $1.29 billion for the quarter, missing the consensus estimate of $1.323 billion according to Ibes data. The top-line miss appeared to overshadow the company's operating income figures, which were also released alongside the revenue report.
Investors reacted swiftly to the shortfall, driving the stock sharply lower in early trading. The decline highlights the market's sensitivity to revenue growth metrics for high-valuation biotech companies like Alnylam.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.